Business Wire

CLEANWATTS

11.8.2022 12:43:09 CEST | Business Wire | Press release

Share
Cleanwatts Presents Soma Demeny as VP of HR

Cleanwatts, the leading climate tech company committed to simplifying, amplifying, and accelerating the energy transition for communities around the world, presents Soma Demeny as VP of HR, assuming the responsibility of leading our most important assets: people .

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220811005340/en/

Soma Demeny began his career in Deutsche Telekom, subsequently spending 17 years with General Electric (GE) where he led human resource teams in Finance, Digital and Corporate divisions. Soma’s international career is centered on helping service and manufacturing organizations scale, grow and adapt to change through the implementation of world-class human resource infrastructures and best practices. More recently, Soma directed much of his time and expertise to help smaller mid-market companies reorganize and adapt to change.

Soma carries degrees in Business Studies and Human Resources Management and is a graduate of GE’s prestigious Human Resources Leadership Program. Soma is Hungarian and has lived in the UK, Austria, and South America. Among Soma’s defining characteristics are curiosity, agility, creativity and fun. As a father of two and a company cultural ambassador, this remains a key philosophy for Soma.

When asked why he joined Cleanwatts, Soma replied pointedly: “Who wouldn’t want to be part of changing the world?”

Cleanwatts’ appointment of Soma Demeny is yet another important decision taken by the company in recent months. It reflects Cleanwatts’ commitment to building a healthy, vibrant and talented organization able to travel at market speed. Michael Pinto, Cleanwatts co-founder and CEO, describes Soma as “a world-class HR Leader, out-of-the-box thinker and a person that connects very easily with people through his critical thinking, emotional intelligence, and clear communication style.”

Soma will be responsible for designing and overseeing the company’s HR strategy, including recruitment and employee retention programs, evaluating and improving the company’s employee value proposition, training and development plans, as well as creating a safe workplace, healthy and inspirational culture as the organization continues to build a world in which clean energy is decentralized, digitalized, and democratized.

Ends

About Cleanwatts

We are a climate tech company committed to simplifying, amplifying, and accelerating the energy transition for communities around the world. We achieve this by optimizing the consumption, generation, storage, trading, and balancing of clean energy, where it matters most: locally.

We deliver value by creating and managing Renewable Energy Communities, deploying our domain expertise, proprietary technology, financial capital, and management capabilities for the benefit of our clients.

At the heart of our offering stands Cleanwatts™ OS, our Operating System specifically designed to manage energy communities. Cleanwatts™ OS is a modular, interoperable, and localizable cloud-based platform that seamlessly connects the dots between behind-the-meter optimization for community members, front-of-the-meter grid resiliency, and transaction management for local energy markets.

We are now actively managing a growing list of over 100 energy communities built by our very own REC Factory: a highly skilled cross-functional team, committed to working closely with anchor clients, town halls, and other community members to develop the best solution for each local community that we serve. Building on the success of our first REC Factory in Portugal, we’re now replicating this level of engagement in other geographies around the world.

We are building a world in which clean energy is decentralized, digitalized, and democratized.

Follow Cleanwatts on LinkedIn

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye